20 reports

  • HUGE MARKET POTENTIAL FOR BREAST CANCER MABS OWING TO PRODUCT APPROVALS

About Breast Cancer mAbs Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates...

  • Cancer
  • United States
  • World
  • Market Size
  • Seattle Genetics, Inc.
  • PIPELINE PORTFOLIO
  • LIST OF PHASE III PIPELINE MOLECULES

About Cancer Monoclonal Antibodies The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Seattle Genetics, Inc.
  • Executive Summary
  • B: ADC Pipeline Analysis, By Drug, Developer, Phase, Indication, Status

ABOUT ## IN ## CASES OF THIS CANCER ARE HER## POSITIVE.

  • Cancer
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • Lymphoma drugs market in Americas
  • Lymphoma drugs market in EMEA

Lymphoma is one of the most prevalent forms of cancers, affecting huge population every year.

  • Cancer
  • Lymphoma
  • United States
  • Forecast
  • Seattle Genetics, Inc.
  • PIPELINE PORTFOLIO
  • MARKET DRIVERS

About Antibody Drug Conjugates ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue. Antibodies are the proteins produced...

  • Cancer
  • Therapy
  • ImmunoGen, Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • PIPELINE PORTFOLIO

About Monoclonal Antibodies Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific,...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Seattle Genetics, Inc.
  • ADCS FOR BREAST CANCER
  • 6. KEY THERAPEUTIC AREAS

INTRODUCTION Since the first approval of MYLOTARG™ in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS®...

  • Cancer
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • Seattle Genetics, Inc.

Hoffmann-La Roche Ltd. ## ## ## ## ## ## ## ## Amgen Inc. ## ## ## ## ## ## ## ## AbbVie Inc. ## ## ## ## ## ## ## ## Source: GlobalData' s Pharma eTrack Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2015 2015 trials are taken as of Augu

  • Cancer
  • Clinical Trial
  • Hospital
  • Lymphoma
  • Seattle Genetics, Inc.
  • SALES MIX - US AND CANADA/INTERNATIONAL
  • TOTAL SALES (SEATTLE GENETICS AND TAKEDA) - GROWING STEADILY IN NICHE MARKET

ANNEXURE Our coverage list: ## cancer drugs ##.

  • Cancer
  • Lymphoma
  • Therapy
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • 10.1 BIBLIOGRAPHY
  • ADCETRIS SWOT ANALYSIS, 2015

NATURE REVIEWS CANCER; ##(##): ##-##.

  • Cancer
  • Epidemiology
  • Therapy
  • World
  • Seattle Genetics, Inc.

This version of the DART molecule enables the cancer-fighting properties of the immune effector cells, such as T lymphocytes, to: (##) recognize and bind to structures expressed on a cancer cell, (##) recruit all types of cytotoxic, or cell killing, T cells, irrespective of

  • Cancer
  • Cell Therapy
  • Cellectis S.A.
  • Janssen Biotech, Inc.
  • Seattle Genetics, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • SEATTLE GENETICS INC
  • Medicines Agency (EMA) scientific advice.

The purpose of one Phase I study is to evaluate cardiac safety of brentuximab vedotin (SGN-##) in patients with CD##-positive cancers.

  • Autoimmune Disease
  • Cancer
  • Dermatological Condition
  • Musculoskeletal Disorder
  • Seattle Genetics, Inc.
  • Seattle Genetics Inc, Major Products and Services
  • Section 2 - Company Analysis

SEA- CD## is under evaluation in a phase ## trial for the treatment of blood cancers and solid tumors.

  • Cancer
  • Therapy
  • United States
  • Company Financials
  • Seattle Genetics, Inc.
  • COPANLISIB HYDROCHLORIDE - DRUG PROFILE
  • Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development

Cisplatin is one of the most commonly utilized treatments for lung, breast and colon cancers.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Seattle Genetics, Inc.
  • Apr 18, 2016: Seattle Genetics Highlights Data on SGN-LIV1A at the American Association for Cancer Research Annual Meeting
  • Apr 18, 2016: Seattle Genetics Highlights Data on 2-fluorofucose (2FF) at the American Association for Cancer Research Annual Meeting

Summary Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer.The company’s lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) indicated for the treatment of relapsed Hodgkin lymphoma...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Seattle Genetics, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development
  • ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) - DORMANT PROJECTS, H1 2016

Cisplatin is one of the most commonly utilized treatments for lung, breast and colon cancers.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Seattle Genetics, Inc.
  • BRENTUXIMAB VEDOTIN - DRUG PROFILE

THE DRUG CANDIDATE HAS POTENTIAL APPLICATIONS IN CANCER AND CANCER PAIN.

  • Autoimmune Disease
  • Cancer
  • Dermatological Condition
  • Musculoskeletal Disorder
  • Seattle Genetics, Inc.
  • ADC PIPELINE OF OXFORD BIOTHERAPEUTICS
  • ADDENDUM 3: ADCS IN IND-ENABLING STUDIES - 2/2

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis This report describes and analyzes the situation of antibody-drug conjugates as of November 2015 regarding ADC pipeline, ADC technologies, ...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • United States
  • Seattle Genetics, Inc.